ReviewF1000Research2017
Recent advances in molecular pathology of craniopharyngioma.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.Neuro-oncology · 2020Trial
- The role of stem cells in pituitary tumour formation.Endocrine-related cancer · 2026Review
- Identifying predictive factors for recurrence risk in pediatric craniopharyngioma after surgery using a clinical prediction model.Discover oncology · 2025Article
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
- Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Current treatment options in oncology · 2024Review
- Predictive Factors for Pediatric Craniopharyngioma Recurrence: An Extensive Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- The molecular pathogenesis of craniopharyngiomas.Archives of endocrinology and metabolism · 2023Review
- Molecular biological features of cyst wall of adamantinomatous craniopharyngioma.Scientific reports · 2023Article
- Management of pediatric craniopharyngioma: 10-year experience from high-flow center.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- A rare challenging case of co-existent craniopharyngioma, acromegaly and squamous cell lung cancer.Endocrinology, diabetes & metabolism case reports · 2018Article
- CRANIOPHARYNGIOMA - CLINICAL AND THERAPEUTIC OUTCOME DATA IN A MIXED COHORT OF ADULT AND PAEDIATRIC CASES.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniopharyngiomas are rare epithelial tumours arising along the path of the craniopharyngeal duct. Two major histological subtypes have been recognised, the papillary and the adamantinomatous. Craniopharyngiomas remain challenging tumours to manage and are associated with significant morbidities and mortality. Recent advances in the molecular pathology of these neoplasms have identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.